FDA committee recommends authorizing Novavax COVID-19 vaccine

Print Friendly, PDF & Email

WASHINGTON — An independent advisory committee voted on Tuesday overwhelmingly in favor of authorizing biotech company Novavax’s protein-based COVID-19 vaccine.

The Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee voted 21-0 with one abstention, in favor of granting Emergency Use Authorization status for the traditional style vaccine.

The final decision will be made by the FDA. The committee is scheduled to meet again June 14-15.

Maryland-based Novax applied for the approval in February of an EUA based on data showing it “would prevent COVID-19 in individuals 18 years of age and older.”

The Novavax vaccine is a more traditional protein-based type of vaccine, employing a whole, deactivated virus.

The two widely used vaccines by Moderna and Pfizer, which have already been approved by the FDA, are mRNA-based.

The single-dose Johnson & Johnson COVID-19 vaccine is the only non-mRNA shot approved for use in the United States by the FDA, though it was limited in May to adults who can’t receive other versions of the vaccine.


Comments are closed.